

Report of the Supervisory Board

The Supervisory Board of CompuGroup Medical SE & Co. KGaA (Supervisory Board) performed the duties incumbent upon it under the law, the Articles of Association and the rules of procedure in financial year 2022. The Supervisory Board monitored the management of the company as carried out by the general partner (represented by its Managing Directors). In accordance with its responsibilities, the Supervisory Board was involved in the key decisions that were of fundamental importance to the company.

The Managing Directors of the general partner consistently informed the Supervisory Board in written and oral reports in a timely and comprehensive manner about all important issues of corporate planning and strategic development, about the business performance, the general position of the group, including any risks, and about risk management.

The Supervisory Board received regular reports from the Managing Directors on the measures taken to increase sales revenue and improve earnings, as well as on major completed company acquisitions.

The Supervisory Board established an Audit Committee. The Committee held a total of seven virtual meetings within the reporting period. Among other matters, the Audit Committee discussed the general partner's interim financial reports and risk reports, prepared Supervisory Board resolutions and discussed key topics with the general partner. In various discussions with the auditors KPMG and the CFO, the Audit Committee has been monitoring the quality of the audit on an ongoing basis. The meetings of the Audit Committee are regularly attended by representatives of the audit firm KPMG.

During the reporting period, the Supervisory Board held five meetings by video conference and one face-to-face meeting; one further resolution was passed by written circulation:

February 16, 2022:

At this meeting, the Supervisory Board was informed about personnel and organizational changes at the level of the general partner's Managing Directors and about the current business performance. The Supervisory Board discussed and approved the update of its competence profile and its rules of procedure. The annual Declaration on Corporate Governance was discussed and approved.

April 5, 2022:

At the meeting, the Supervisory Board discussed the annual financial statements and the consolidated financial statements with the representatives of the general partner (Dr. Dirk Wössner (CEO), Michael Rauch (CFO)) and the auditor (KPMG AG, Berlin, Frankfurt am Main branch). Following the discussion and also based on the preliminary audit and the recommendation of the Audit Committee, the Supervisory Board approved the annual financial statements of CompuGroup Medical SE & Co. KGaA, the consolidated financial statements of CompuGroup Medical group, the dependency report of the general partner, the remuneration report and the non-financial report for financial year 2021. The Supervisory Board also resolved that the annual financial statements of CompuGroup Medical SE & Co. KGaA be submitted to the Annual General Meeting on May 19, 2022 for approval. The Supervisory Board concurred with the general partner's proposal for the appropriation of profits. The Supervisory Board resolved to propose to the Annual General Meeting that the actions of the general partner and the members of the Management Board of the legal predecessor, CompuGroup Medical SE, as well as the actions of the members of the Supervisory Board of the company and of the legal predecessor, CompuGroup Medical SE, be formally approved for financial year 2021. The

Report of the Supervisory Board

Supervisory Board's report to the Annual General Meeting was approved. On the basis of the German COVID-19 Mitigation Act and after considering the pandemic situation and the interests of the shareholders and other participants, the Supervisory Board decided to hold the Annual General Meeting as a virtual general meeting again. The agenda and the proposed resolutions for the Annual General Meeting were discussed and approved by the Supervisory Board. The Supervisory Board received the general partner's current risk report and discussed it with the Managing Directors.

The Supervisory Board discussed and unanimously approved an update of the Declaration of Conformity to be carried out in the course of the year.

May 18, 2022:

In this meeting, the Supervisory Board discussed current topics in connection with the Annual General Meeting to be held the following day.

June 2, 2022:

The Supervisory Board discussed and unanimously approved the conclusion of a termination agreement with Dr. Dirk Wössner.

July 6, 2022:

The Supervisory Board unanimously approved by circular resolution the update of the Declaration of Conformity during the year.

September 19, 2022:

The spokesman for the Managing Directors Michael Rauch reported to the Supervisory Board on the current business performance and discussed it with the Supervisory Board. Philip Heßen (CHRO) provided information on current HR topics, while Managing Director Emanuele Mugnani (AIS Europe) explained growth opportunities for international business areas in his area of responsibility. The Supervisory Board discussed and approved a related party transaction that required its approval.

December 12, 2022:

The spokesman for the Managing Directors Michael Rauch reported to the Supervisory Board on the current business performance and discussed it with the Supervisory Board. Derek Pickell (CEO Northern America & India) presented strategic direction and current topics of the USA & India business unit to the Supervisory Board. At the meeting, the Supervisory Board discussed and unanimously approved the current draft of the joint declaration of compliance pursuant to section 161 German Stock Corporation Act (AktG). The updated competence profile of the Supervisory Board was discussed and the current status of its implementation was documented. On the basis of the new provisions in the German Stock Corporation Act (AktG), the Supervisory Board discussed the concept for the Annual General Meeting 2023 and approved the Annual General Meeting to be held as a virtual Annual General Meeting. At the same meeting, the Supervisory Board discussed the assessment of its own activities and their effectiveness. Based on the evaluation of a questionnaire that had been filled in prior to the meeting, possible areas for improvement were discussed and debated with the general partner.

Report of the Supervisory Board

Conflicts of interest:

There were no conflicts of interest in the Supervisory Board during the reporting period.

Changes in the composition of the Supervisory Board:

The member of the Supervisory Board Dr. Michael Fuchs passed away on December 25, 2022. It is with great sadness that the Supervisory Board learned of his passing and remains grateful to Dr. Fuchs for his valuable contributions.

Mr. Reinhard Lyhs was appointed as a new member of the Supervisory Board with effect from March 1, 2023 by the Koblenz Local Court pursuant to Section 104 Par. 2 German Stock Corporation Act (AktG). The Supervisory Board intends to propose Reinhard Lyhs as the successor of Dr. Michael Fuchs at the Annual General Meeting on May 17, 2023.

Overview of attendance at meetings of the Supervisory Board and the Audit Committee, including the respective meeting formats:

Member/Meeting/Resolution	Supervisory Board (Meeting attendance)					
	Feb 16, 2022	April 5, 2022	May 18, 2022	Jun 2, 2022	Sep 19, 2022	Dec 12, 2022
Date						
Meeting format	Virtual	Virtual	Virtual	Virtual	Presence	Virtual
von Ilberg, Philipp (Chair)	YES	YES	YES	YES	YES	YES
Weinmann, Stefan (Vice Chair)	YES	YES	YES	YES	YES	YES
Basal, Ayfer	YES	YES	YES	YES	YES	YES
Betz, Frank	YES	YES	YES	YES	YES	YES
Fuchs, Michael, Dr. (verstorben am 25.12.2022)	YES	YES	YES	YES	YES	YES
Handel, Ulrike, Dr.	YES	YES	YES	YES	YES	YES
Hegemann, Adelheid	YES	YES	YES	YES	YES	YES
Johnke, Lars	YES	YES	YES	YES	YES	YES
Köhrmann, Martin, Prof. Dr.	YES	YES	YES	YES	YES	YES
Mole, Julia	YES	YES	YES	YES	YES	YES
Störmer, Matthias	YES	YES	YES	YES	YES	YES
Volkens, Bettina, Dr.	YES	YES	YES	YES	YES	YES

Report of the Supervisory Board

Member/Meeting/Resolution	Audit Committee (Meeting attendance)						
	Feb 2, 2022	Mar 9, 2022	Apr 4, 2022	May 3, 2022	Aug 2, 2022	Nov 2, 2022	Dec 15, 2022
Date							
Session format	Virtual	Virtual	Virtual	Virtual	Virtual	Virtual	Virtual
Störmer, Matthias (Chair)	YES	YES	YES	YES	YES	YES	YES
von Ilberg, Philipp	YES	YES	YES	YES	YES	YES	YES
Basal, Ayfer	YES	YES	YES	YES	YES	YES	YES
Johnke, Lars	YES	YES	YES	YES	YES	YES	YES

Audit of the 2022 financial statements:

The Managing Directors of the general partner submitted to the members of the Audit Committee and the Supervisory Board the annual financial statements and consolidated financial statements for financial year 2022, the Combined Management Report of CompuGroup Medical SE & Co. KGaA and the entire group for financial year 2022, the remuneration report for financial year 2022, the separate non-financial report for the group and the dependency report of the general partner once this had been prepared.

The auditing firm (KPMG) elected and appointed as auditor by the Supervisory Board at the Annual General Meeting of CompuGroup Medical SE & Co. KGaA on May 19, 2022 audited the annual financial statements of CompuGroup Medical SE & Co. KGaA, the consolidated financial statements and the Combined Management Report of CompuGroup Medical SE & Co. KGaA and the group as at December 31, 2022, including the accounting system, in accordance with the statutory provisions and issued an unqualified audit opinion.

At meetings on March 8, 2023 and then on March 20, 2023, the members of the Audit Committee discussed in detail the annual financial statements, the consolidated financial statements, the Combined Management Report of CompuGroup Medical SE & Co. KGaA, the remuneration report and the separate non-financial report for the group as well as the auditor's findings. The auditor reported on the main findings of the audit. On this basis, the Audit Committee proposed to the Supervisory Board to approve the financial statements prepared by the general partner.

The Supervisory Board was informed of the audit results at a meeting on March 8, 2023 and took note of the Audit Committee's recommendation. At its meeting on March 22, 2023, the Supervisory Board was presented with the annual financial statements for financial year 2022 as prepared by the general partner, the consolidated financial statements and the management report of CompuGroup Medical SE & Co. KGaA and the group, as well as the general partner's proposal for the appropriation of net profit, the dependency report, the remuneration report, the separate non-financial report of the group and the corresponding auditor's findings and report. The Supervisory Board examined the documents submitted. Employees of the auditing firm KPMG personally answered all the Supervisory Board's questions in detail.

FOR OUR SHAREHOLDERS

Report of the Supervisory Board

The Supervisory Board acknowledged the auditor's findings and raised no objections.

In accordance with section 171 (1) German Stock Corporation Act (AktG), the Supervisory Board has reviewed and approved the annual financial statements of the parent company and the group, and the management reports of CompuGroup Medical SE & Co. KGaA and the group, in addition to the proposal for the appropriation of net profit and the risk report. In accordance with section 286 (1) German Stock Corporation Act (AktG), the annual financial statements of CompuGroup Medical SE & Co. KGaA are forwarded to the company's Annual General Meeting for adoption. The consolidated financial statements were approved. The Supervisory Board approved the general partner's proposal for the appropriation of profits. The remuneration report and the separate non-financial report were approved.

The general partner submitted its report on relations with associated companies (dependency report) in accordance with section 312 German Stock Corporation Act (AktG), and its declaration in accordance with section 312 (3) German Stock Corporation Act (AktG), to the Supervisory Board. The auditor has reviewed the dependency report and issued the following opinion on the corresponding findings:

"Based on our audit and assessment, which we have carried out in accordance with professional standards, we hereby confirm that the factual statements made in the report are correct, the company's compensation with respect to the transactions listed in the report was not inappropriately high."

The Supervisory Board acknowledged and approved the auditor's findings and also reviewed the dependency report. According to the final results of the review by the Supervisory Board, there are no objections to the declaration by the general partner at the end of the dependency report.

The Supervisory Board would like to thank all Managing Directors and all employees of CompuGroup Medical SE & Co. KGaA and its associated companies for their commitment and hard work in the past financial year.

Koblenz, March 22, 2023



Philipp von Ilberg
(Chairman of the Supervisory Board)